Kuk Hyoun Hwang - Feb 9, 2023 Form 3 Insider Report for Bellevue Life Sciences Acquisition Corp. (BLAC)

Role: Chief Executive Officer and President, Director, 10%+ Owner
Signature: /s/ Kuk Hyoun Hwang
Stock symbol: BLAC
Transactions as of: Feb 9, 2023
Transactions value $: $0
Form type: 3
Date filed: 2/9/2023, 03:45 PM
Next filing: Feb 16, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BLAC	Common Stock						1.73M	Feb 9, 2023	By Bellevue Global Life Sciences Investors LLC	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC ("Bellevue Global"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by Bellevue Global.
F2	Includes up to 225,000 shares subject to forfeiture depending on the extent to which the underwriters' over-allotment is exercised, if at all.
F3	Includes 680,000 shares of common stock held by Bellevue Global, which pursuant to a convertible promissory note between Bellevue Global and BCM Europe AG, a wholly-owned subsidiary of Bellevue Capital, the principal amount of $3,400,000 can be converted into 680,000 shares of common stock at the election of Bellevue Global or BCM Europe AG on or after the commencement of the initial public offering of the common stock. Mr. Hwang has voting and dispositive power over the transfer of such shares to BCM Europe.

Remarks:

Chief Executive Officer and President